New artificial intelligence system can detect eight abnormalities, potentially facilitating radiology reporting, diagnosis, and treatment.
GE Healthcare, in partnership with South Korean medical artificial intelligence (AI)company Lunit, has released its Thoracic Care Suite, an AI suite designed to ease the workload associated with COVID-19.
This eight-algorithm AI suite is designed to quickly analyze chest X-ray findings and flags any abnormalities, such as pneumonia, for further radiologist review. The suite can also pinpoint tuberculosis, lung nodules, atelectasis, calcification, cardiomegaly, fibrosis, mediastinal widening, and pleural effusion detection.
“The launch of our Thoracic Care Suite is part of GE Healthcare’s larger effort to help ensure clinicians and partners on the front lines have the equipment they need to quickly diagnose and effectively treat COVID-19 patients,” said Kieran Murphy, GE Healthcare president and chief executive officer, in a statement. “The pandemic has proven that data, analytics, AI, and connectivity will only become more central to delivering care...This new offering is the latest example of how X-ray and AI can uphold the highest standard of patient care amidst the most modern of disease threats.”
With the number of COVID-19 cases topping 8 million worldwide, radiologists could benefit from an AI tool that can automatically analyze images for characteristics typical of COVID-19 infection, Murphy said. The Thoracic Suite inserts an abnormality score into a flagged radiology report, as well as an image overlay, and a written location description that can potentially facilitate diagnosis and treatment.
In particular, according to company information, the Thoracic Suite can identify high-risk cases and monitor patients who are beginning to show either progression or regression of mild respiratory symptoms. Company data indicates the suite has a 97 percent-to-99 percent accuracy rate, and one study indicated it could reduce reading time per scan by 34 percent.
Based on the company statement, the suite is available for GE Healthcare’s global fixed, mobile, and R&F X-ray customers at the point of sale without any annual fees. In addition, installation does not require customers to engage with any enterprise information technology projects, potentially lowering the barrier for adopting AI.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.